




Rijksinstituut voor Volksgezondheid
en Milieu
*Ministerie van Volksgezondheid,
Welzijn en Sport*

The importance of national surveillance on antimicrobial resistance

The Dutch example

Nienke van de Sande-Bruinsma
Epidemiology and Surveillance
RIVM, The Netherlands

The Dutch AMR situation




Cipro R *E.coli*: 7% in 2003 to 14% in 2010

Now yellow!



Maasstad Ziekenhuis faalt bij aanpak resistentie



Klebsiella pneumoniae
Wikimedia Commons

Toegevoegd: dinsdag 31 mei 2011, 17:04
Door redacteur gezondheidszorg
Rinke van den Brink

Het [Maasstad Ziekenhuis in Rotterdam](#) worstelt al zeven maanden met een uitbraak van een zeer gevaarlijke en nagenoeg onbehandelbare bacterie. Het ziekenhuis doet pas sinds afgelopen donderdag onderzoek naar de bacterie.



Introduction: Know your enemy

With the increasing antimicrobial resistance rates, surveillance is an essential tool to:

- monitor trends
- rapidly detect / actively react to new resistance elevations
- evaluate policies
- compare laboratory results for quality improvement





International <> National <> Local Hospital

Interaction between layers is essential for surveillance:

- Awareness
- More insight in your data (translation to improved patient care)
- Standardisation/Quality improvement
- Communication/Exchange of knowledge

Knowing what is going on at your neighboring hospital or country is essential for combined action against AMR.



The Dutch surveillance system ISIS-AR


For this purpose, the Dutch Infectious Diseases Surveillance Information System on Antibiotic Resistance (ISIS-AR) and the interactive database ISISweb were developed.

Multidisciplinary ISIS-AR team started in July 2007

Now, in 2011 30 of the 66 Dutch Medical Microbiology Laboratories are participating


Goals ISIS-AR

- Monitor AMR trends (Nethmap, EARS-net)
- Produce 'mirror' data (improve patient care)
 - > Feedback reports
 - > ISISweb
- 'Early' detection of (multi-)institutional elevations
- Active response to new resistance development (guidelines)





How does it work?: Dataflow ISIS-AR and ISISweb





ISIS-AR methodology

- Data are collected on a monthly basis
- Only standardised data are collected, no free text
- Clinically relevant micro-organisms (>50)
- All positive cultures with an antibiogram
- Included: Culture site (material), Distinction between screening and clinical isolates.
- S I R interpretation, MIC-values, diameters (if available) and E-test and Confirmation results are collected
- Patient information, Institution (Hospital, OPD, GP, Nursing homes) Department (at least ICU/non-ICU)
- For analysis purposes; first isolate per patient per year, but all successive cultures per patient are collected



Feedback report

- Overview of dataset
- Datamanager check of data send in to RIVM. If necessary consultation with medical microbiologist.
- Table with unknown values
- Table unusual resistance phenotypes are included, and have to be confirmed by the medical microbiologist.
- Medical microbiologist of ISIS-AR team can contact the lab in case of special findings that are worrisome.
- After confirmation the data go online.
- Improvement of quality, awareness and communication!

Aanlevering	
Lab-code	ISIS002
Maand	April
Jaar	2011
Aanlevering-ID	4194
Datum	14-07-2011

Onbekende sleutelwaarden			
Gegeven	Onbekende waarde	Aantal	Soort
AFDELING	HOOG2	1	monsters


Totaal Overzichten			
#Isolaten ISIS	#Isolaten	#Patienten ISIS	#Patienten
1619	1802	764	817

Samenvatting Bijzondere Resistenties			
Antibiotica-paathoogen combinaties	#Pat	#Iso	Monster.Isolaatvolgnr
Moraxella catarrhalis intermediair/resistent t.o.v. ceftriaxon (TR07)	1	1	11-530555.2
Overige Enterobacteriaceae (excl. Proteus/Morganella) resistent t.o.v. carbapenem (TR07a)	1	1	11-526400.1
Acinetobacter spp. carbapenem resistent (TR07a)	3	8	11-526412.1, 11-527796.1, 11-528068.1, 11-532577.1, 11-532582.1, 11-532584.1, 11-532831.1, 11-525604.1
Overige Enterococcus spp. penicilline groep en vancomycine resistent (TR07a)	1	1	11-525095.1
6.2a Coagulase-negatieve staphylococci Resistent to vancomycin (TR08b)	1	1	11-531927.1



www.isis-web.nl

- Public en closed part
- National overviews and trends
- Data 'mirroring'
- Next year: multidrug resistance en standard reports for hospital board and inspection.





Source

Patient characteristics, time period, isolate selection

ISISwel

Afdrukken

Bron

- ☐ Eigen laboratorium
- ☐ Samenwerkingsverband
- ☒ Landelijk

Zorgclassificatie

Patiënt

Leeftijdsgroep van: 0 t/m 4 tot en met: 65 en ouder

EM, EV, EO, bekend

Clinical or screeningsisolation site (blood, wound, urine)

Setting (hospital, OPD, GP, Nursing home), Department, Specialisation

Opnameplaats: Eerste isolaat

Lab aanvraag

Instelling

Test reden	Instellingstype
1 testreden	Alle
Materiaal	Afdelingstype
Alle	Alle
Materiaal uitgebreid	Specialisme
Maak een keuze	Alle

Output (table or graphs): overview per antibiotic or MO, compare between categories, trend analysis, compare between labs

Uitvoer

Uitvoeropties

Type: Resistentie-overzicht - grafiek antibioticum

☒ Ongestackt ☐ Gestackt


Gevoeligheid: ☒ S ☒ I ☒ R

Genereren

Reset Selectie




Example ISISweb: Trends





Example ISISweb: Comparison between settings





Wake up call: OXA-48 outbreak in Dutch hospital

- 31 may 2011 outbreak of CPE was officially reported, but was going on already for some time...
- Lot of media attention that lead to political and social discussions, how to prevent these outbreaks in the future
- Due to the late discovery of the outbreak and delayed action, 4.340 patients had to be screened for possible contamination
- In total 115 patients carried the Klebsiella OXA-48
- End of July the outbreak was under control!
- Interim report Health Inspectorate october 2011. Title: Klebsiella outbreak in Maasstad hospital avoidable.
- The final report will be available in the beginning 2012; was the outbreak also blameworthy.



How to prevent these outbreaks in the future

Carbapenemase producing organisms:

- Guideline for Carbapenemase detection and infection control
- CPE surveillance in place for confirmation at RIVM ('connected' with ISIS-AR)
- ISIS-AR as a back-up to detect (multi)-institutional elevations

In general:

- Consultation of representatives of MoH, Health Inspectorate, CIB-RIVM, NVMM, SWAB, WIP, VHIG
 - Signaling structure (monthly) and response team for Healthcare associated infections, specific focus on unusual and multidrug resistance
 - Expanding ISIS-AR (each laboratory should be able to participate) and implement 'outbreak' algorithm (structural detection of defined fenotypes)
 - National Laboratory reference structure for typing





Thanks to all participating laboratories and the ISIS-AR team

- Jan Muilwijk – epidemiologist
- Jeroen Alblas – datamanager
- Jos Monen – datamanager
- Maurine Leverstein – van Hall – medical microbiologist
- Akke van der Bij – medical microbiologist
- Daan Notermans – medical microbiologist
- Marlieke de Kraker – epidemiologist
- Nienke van de Sande – project leader
- Sabine de Greeff – AMR projectleader

